Compare MYO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | PLUR |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 34.9M |
| IPO Year | 2017 | N/A |
| Metric | MYO | PLUR |
|---|---|---|
| Price | $1.01 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 830.5K | 47.8K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,643,203.00 | $1,326,000.00 |
| Revenue This Year | $24.07 | $97.38 |
| Revenue Next Year | $17.48 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 65.00 | ★ 121.74 |
| 52 Week Low | $0.71 | $3.02 |
| 52 Week High | $7.17 | $7.13 |
| Indicator | MYO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 38.26 |
| Support Level | $1.02 | $3.10 |
| Resistance Level | $1.13 | $3.92 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 59.57 | 16.25 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.